Chronic Rhinosinusitis Linked to Increased Risk of Other Diseases

This article originally appeared here.
Share this content:
Chronic Rhinosinusitis Linked to Increased Risk of Other Diseases
Chronic Rhinosinusitis Linked to Increased Risk of Other Diseases

TUESDAY, Sept. 8, 2015 (HealthDay News) -- Chronic rhinosinusitis (CRS) is associated with increased risk of other diseases, with different patterns based on CRS phenotype, according to research published online Aug. 31 in Allergy.

Annemarie G. Hirsch, Ph.D., M.P.H., from the Geisinger Health System in Danville, Pa., and colleagues examined the risk of incident disease within five years after a new diagnosis of CRS with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP). Data were included from a case-control study nested within a longitudinal cohort of primary care patients.

The researchers found that, compared with controls, the 3,612 CRSsNP cases had increased risk for incidence of upper airway diseases, including adenotonsillitis (hazard ratio [HR], 3.29); lower aerodigestive tract disease, including asthma (HR, 2.69); epithelial conditions, including atopic dermatitis (HR, 2.75); and hypertension (HR, 1.38). Compared with controls, the 241 CRSwNP cases had increased risk for obesity (HR, 1.74); there was no correlation for CRSwNP with other diseases.

"The risk of other diseases associated with CRS adds to the burden of an already highly burdensome condition, and suggests either that CRS promotes onset of other diseases or is an indicator of systemic disease processes," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »